fulvestrant,capivasertib
otsuka,astrazeneca
['capitello-291', 'capitello,291', 'mbc', 'capivasertib']
 asco 2023 dr. , from , has been a driving force in the groundbreaking #capitello-291 trial! at #asco23 she discusses #capivasertib, in combination with #fulvestrant for patients with hormone receptor-positive mbc. 
Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.